hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA
Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilibrative nucleoside transporter 1 (hENT1) predicts adjuvant gemcitabine treatment benefit over 5-FU. Cytidine deaminase (CDA), inside or outside of the cancer cell, will deaminate gemcitabine, altering...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 November 2021
|
| In: |
Cancers
Year: 2021, Jahrgang: 13, Heft: 22, Pages: 1-15 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13225758 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers13225758 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/13/22/5758 
|
| Verfasserangaben: | Karen Aughton, Nils O. Elander, Anthony Evans, Richard Jackson, Fiona Campbell, Eithne Costello, Christopher M. Halloran, John R. Mackey, Andrew G. Scarfe, Juan W. Valle, Ross Carter, David Cunningham, Niall C. Tebbutt, David Goldstein, Jennifer Shannon, Bengt Glimelius, Thilo Hackert, Richard M. Charnley, Alan Anthoney, Markus M. Lerch, Julia Mayerle, Daniel H. Palmer, Markus W. Büchler, Paula Ghaneh, John P. Neoptolemos and William Greenhalf |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 178680302X | ||
| 003 | DE-627 | ||
| 005 | 20220820112306.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220121s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13225758 |2 doi | |
| 035 | |a (DE-627)178680302X | ||
| 035 | |a (DE-599)KXP178680302X | ||
| 035 | |a (OCoLC)1341439014 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Aughton, Karen |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA |c Karen Aughton, Nils O. Elander, Anthony Evans, Richard Jackson, Fiona Campbell, Eithne Costello, Christopher M. Halloran, John R. Mackey, Andrew G. Scarfe, Juan W. Valle, Ross Carter, David Cunningham, Niall C. Tebbutt, David Goldstein, Jennifer Shannon, Bengt Glimelius, Thilo Hackert, Richard M. Charnley, Alan Anthoney, Markus M. Lerch, Julia Mayerle, Daniel H. Palmer, Markus W. Büchler, Paula Ghaneh, John P. Neoptolemos and William Greenhalf |
| 264 | 1 | |c 17 November 2021 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.01.2022 | ||
| 520 | |a Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilibrative nucleoside transporter 1 (hENT1) predicts adjuvant gemcitabine treatment benefit over 5-FU. Cytidine deaminase (CDA), inside or outside of the cancer cell, will deaminate gemcitabine, altering transporter affinity. ESPAC-3(v2) was a pancreatic cancer trial comparing adjuvant gemcitabine and 5-FU. Tissue microarray sections underwent in situ hybridization and immunohistochemistry. Analysis of both CDA and hENT1 was possible with 277 patients. The transcript did not correlate with protein levels for either marker. High hENT1 protein was prognostic with gemcitabine; median overall survival was 26.0 v 16.8 months (p = 0.006). Low CDA transcript was prognostic regardless of arm; 24.8 v 21.2 months with gemcitabine (p = 0.02) and 26.4 v 14.6 months with 5-FU (p = 0.02). Patients with low hENT1 protein did better with 5-FU, but only if the CDA transcript was low (median survival of 5-FU v gemcitabine; 29.3 v 18.3 months, compared with 14.2 v 14.6 with high CDA). CDA mRNA is an independent prognostic biomarker. When added to hENT1 protein status, it may also provide treatment-specific predictive information and, within the frame of a personalized treatment strategy, guide to either gemcitabine or 5FU for the individual patient. | ||
| 650 | 4 | |a 5-fluorouracil | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a gemcitabine | |
| 650 | 4 | |a predictive marker | |
| 650 | 4 | |a prognostic marker | |
| 650 | 4 | |a pyrimidine | |
| 700 | 1 | |a Elander, Nils O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Evans, Anthony |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jackson, Richard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Campbell, Fiona |e VerfasserIn |4 aut | |
| 700 | 1 | |a Costello, Eithne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Halloran, Christopher M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mackey, John R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scarfe, Andrew G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Valle, Juan W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carter, Ross |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cunningham, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tebbutt, Niall C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldstein, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shannon, Jennifer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glimelius, Bengt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hackert, Thilo |d 1971- |e VerfasserIn |0 (DE-588)122158512 |0 (DE-627)70579346X |0 (DE-576)182659208 |4 aut | |
| 700 | 1 | |a Charnley, Richard M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anthoney, Alan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lerch, Markus M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mayerle, Julia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Palmer, Daniel H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Büchler, Markus W. |d 1955- |e VerfasserIn |0 (DE-588)120893339 |0 (DE-627)080952526 |0 (DE-576)292434146 |4 aut | |
| 700 | 1 | |a Ghaneh, Paula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Neoptolemos, John P. |e VerfasserIn |0 (DE-588)172283302 |0 (DE-627)697192954 |0 (DE-576)133150879 |4 aut | |
| 700 | 1 | |a Greenhalf, William |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 13(2021), 22, Artikel-ID 5758, Seite 1-15 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:22 |g elocationid:5758 |g pages:1-15 |g extent:15 |a hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13225758 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/22/5758 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220121 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 172283302 |a Neoptolemos, John P. |m 172283302:Neoptolemos, John P. |d 910000 |d 910200 |e 910000PN172283302 |e 910200PN172283302 |k 0/910000/ |k 1/910000/910200/ |p 25 | ||
| 998 | |g 120893339 |a Büchler, Markus W. |m 120893339:Büchler, Markus W. |d 910000 |d 910200 |e 910000PB120893339 |e 910200PB120893339 |k 0/910000/ |k 1/910000/910200/ |p 23 | ||
| 998 | |g 122158512 |a Hackert, Thilo |m 122158512:Hackert, Thilo |d 910000 |d 910200 |d 50000 |e 910000PH122158512 |e 910200PH122158512 |e 50000PH122158512 |k 0/910000/ |k 1/910000/910200/ |k 0/50000/ |p 17 | ||
| 999 | |a KXP-PPN178680302X |e 4040688813 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"178680302X","id":{"eki":["178680302X"],"doi":["10.3390/cancers13225758"]},"name":{"displayForm":["Karen Aughton, Nils O. Elander, Anthony Evans, Richard Jackson, Fiona Campbell, Eithne Costello, Christopher M. Halloran, John R. Mackey, Andrew G. Scarfe, Juan W. Valle, Ross Carter, David Cunningham, Niall C. Tebbutt, David Goldstein, Jennifer Shannon, Bengt Glimelius, Thilo Hackert, Richard M. Charnley, Alan Anthoney, Markus M. Lerch, Julia Mayerle, Daniel H. Palmer, Markus W. Büchler, Paula Ghaneh, John P. Neoptolemos and William Greenhalf"]},"person":[{"role":"aut","display":"Aughton, Karen","roleDisplay":"VerfasserIn","given":"Karen","family":"Aughton"},{"role":"aut","family":"Elander","display":"Elander, Nils O.","roleDisplay":"VerfasserIn","given":"Nils O."},{"role":"aut","family":"Evans","display":"Evans, Anthony","roleDisplay":"VerfasserIn","given":"Anthony"},{"family":"Jackson","given":"Richard","roleDisplay":"VerfasserIn","display":"Jackson, Richard","role":"aut"},{"given":"Fiona","roleDisplay":"VerfasserIn","display":"Campbell, Fiona","family":"Campbell","role":"aut"},{"role":"aut","family":"Costello","roleDisplay":"VerfasserIn","given":"Eithne","display":"Costello, Eithne"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Halloran, Christopher M.","given":"Christopher M.","family":"Halloran"},{"roleDisplay":"VerfasserIn","display":"Mackey, John R.","given":"John R.","family":"Mackey","role":"aut"},{"family":"Scarfe","roleDisplay":"VerfasserIn","display":"Scarfe, Andrew G.","given":"Andrew G.","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Juan W.","display":"Valle, Juan W.","family":"Valle","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Ross","display":"Carter, Ross","family":"Carter","role":"aut"},{"roleDisplay":"VerfasserIn","given":"David","display":"Cunningham, David","family":"Cunningham","role":"aut"},{"display":"Tebbutt, Niall C.","roleDisplay":"VerfasserIn","given":"Niall C.","family":"Tebbutt","role":"aut"},{"family":"Goldstein","given":"David","roleDisplay":"VerfasserIn","display":"Goldstein, David","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Jennifer","display":"Shannon, Jennifer","family":"Shannon","role":"aut"},{"role":"aut","family":"Glimelius","roleDisplay":"VerfasserIn","given":"Bengt","display":"Glimelius, Bengt"},{"role":"aut","family":"Hackert","display":"Hackert, Thilo","roleDisplay":"VerfasserIn","given":"Thilo"},{"family":"Charnley","roleDisplay":"VerfasserIn","given":"Richard M.","display":"Charnley, Richard M.","role":"aut"},{"role":"aut","family":"Anthoney","display":"Anthoney, Alan","roleDisplay":"VerfasserIn","given":"Alan"},{"given":"Markus M.","roleDisplay":"VerfasserIn","display":"Lerch, Markus M.","family":"Lerch","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Julia","display":"Mayerle, Julia","family":"Mayerle","role":"aut"},{"role":"aut","display":"Palmer, Daniel H.","roleDisplay":"VerfasserIn","given":"Daniel H.","family":"Palmer"},{"roleDisplay":"VerfasserIn","display":"Büchler, Markus W.","given":"Markus W.","family":"Büchler","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Paula","display":"Ghaneh, Paula","family":"Ghaneh","role":"aut"},{"display":"Neoptolemos, John P.","roleDisplay":"VerfasserIn","given":"John P.","family":"Neoptolemos","role":"aut"},{"role":"aut","given":"William","roleDisplay":"VerfasserIn","display":"Greenhalf, William","family":"Greenhalf"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA","title":"hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA"}],"origin":[{"dateIssuedDisp":"17 November 2021","dateIssuedKey":"2021"}],"note":["Gesehen am 21.01.2022"],"physDesc":[{"extent":"15 S."}],"relHost":[{"origin":[{"dateIssuedKey":"2009","publisherPlace":"Basel","dateIssuedDisp":"2009-","publisher":"MDPI"}],"language":["eng"],"disp":"hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNACancers","physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 27.05.2020"],"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"pubHistory":["1.2009 -"],"recId":"614095670","id":{"zdb":["2527080-1"],"eki":["614095670"],"issn":["2072-6694"]},"title":[{"title_sort":"Cancers","title":"Cancers"}],"part":{"pages":"1-15","year":"2021","issue":"22","text":"13(2021), 22, Artikel-ID 5758, Seite 1-15","extent":"15","volume":"13"},"type":{"media":"Online-Ressource","bibl":"periodical"}}],"language":["eng"]} | ||
| SRT | |a AUGHTONKARHENT1PREDI1720 | ||